REVIEW ARTICLE/BRIEF REVIEW
Worldwide management of donors after neurological death:
a systematic review and narrative synthesis of guidelines
Prise en charge des donneurs apre`s un de´ce`s neurologique dans le
monde : revue syste´matique et synthe`se narrative des lignes
directrices
Anne Julie Frenette, PharmD, PhD . David Williamson, BPharm, PhD . Matthew-John Weiss, MD .
Bram Rochwerg, MD, MSc, FRCPC . Ian Ball, MD, MSc . Dave Brindamour, BPharm, MSc .
Karim Serri, MD . Frederick D’Aragon, MD, MSc . Maureen O. Meade, MD, MSc .
Emmanuel Charbonney, MD, PhD
Received: 23 April 2020 / Revised: 2 July 2020 / Accepted: 2 July 2020 / Published online: 18 September 2020
 Canadian Anesthesiologists’ Society 2020
Abstract
Objective The objectives of this study were to
systematically identify and describe guidelines for the
care of neurologically deceased donors and to evaluate
their methodological quality, with the aim of informing and
supporting the new Canadian guidelines for the
management of organ donors.
Methodology Following a systematic search, we included
any document endorsed by an organ donation
organization, a professional society, or a government,
that aims to direct the medical management of adult,
neurologically deceased, multi-organ donors. We extracted
recommendations pertaining to six domains: the autonomic
storm, hemodynamic instability, hormone supplementation,
ventilation, blood product transfusions, and general
intensive care unit (ICU) care. Methodological quality of
the guidelines was assessed by the validated AGREE-II
tool.
A. J. Frenette, PharmD, PhD (&)
Department of Pharmacy, Hoˆpital du Sacre´-Cœur de Montre´al,
Montreal, QC, Canada
e-mail: anne.julie.frenette@umontreal.ca
Faculte´ de Pharmacie, Universite´ de Montre´al, Montreal, QC,
Canada
Faculte´ de Me´decine, Universite´ de Montre´al, Montreal, QC,
Canada
Centre de recherche CIUSSSS du Nord de L’Ile, Hoˆpital du
Sacre´-Coeur de Montre´al, 5400 Gouin Ouest, Montre´al, QC H4J
1C5, Canada
D. Williamson, BPharm, PhD
Department of Pharmacy, Hoˆpital du Sacre´-Cœur de Montre´al,
Montreal, QC, Canada
Faculte´ de Pharmacie, Universite´ de Montre´al, Montreal, QC,
Canada
Centre de recherche CIUSSSS du Nord de L’Ile, Hoˆpital du
Sacre´-Coeur de Montre´al, 5400 Gouin Ouest, Montre´al, QC H4J
1C5, Canada
M.-J. Weiss, MD
Population Health and Optimal Health Practices Research Unit,
Trauma-Emergency-Critical Care Medicine, CHU de Que´bec,
Universite´ Laval Research Center, Quebec, QC, Canada
Pediatrics Department, Intensive Care Division, Faculte´ de
Me´decine, Universite´ Laval, Quebec, QC, Canada
Transplant Que´bec, Montreal, QC, Canada
B. Rochwerg, MD, MSc, FRCPC
Department of Medicine, McMaster University, Hamilton, ON,
Canada
Department of Health Research Methods, Evidence and Impact,
McMaster University, Hamilton, ON, Canada
I. Ball, MD, MSc
Department of Medicine, Western University, London, ON,
Canada
D. Brindamour, BPharm, MSc
Department of Pharmacy, Hoˆpital du Sacre´-Cœur de Montre´al,
Montreal, QC, Canada
123
Can J Anesth/J Can Anesth (2020) 67:1839–1857
https://doi.org/10.1007/s12630-020-01815-0

Main findings This review includes 27 clinical practice
guidelines representing 26 countries published between
1993 and 2019. Using the AGREE-II validated tool for the
evaluation of guidelines’ quality, documents generally
scored well on their scope and clarity of presentation.
Nevertheless, quality was limited in terms of the scientific
rigor of guideline development. Recommendations varied
substantially across the domains of managing the
autonomic storm, subsequent management of
hemodynamic instability, hormone therapy, mechanical
ventilation, blood product transfusion, and general ICU
care. We found consistent recommendations for low tidal
volume ventilation subsequent to the publication of a
landmark clinical trial.
Conclusion Highly inconsistent recommendations for
deceased donor care summarized in this review likely
reflect the relatively slow emergence of high-quality
clinical research in this field, as well as a late uptake of
recent validated guideline methodology. Even in this
context of few randomized-controlled trials, our group
supported the need for new Canadian guidelines for the
management of organ donors that follow rigorous
recognized methodology and grading of the evidence.
Trial registration PROSPERO (CRD42018084012);
registered 25 February 2016.
Re´sume´
Objectif Les objectifs de cette e´tude e´taient d’identifier et
de de´crire de fac¸on syste´matique les lignes directrices
concernant les soins a` prodiguer aux donneurs suivant un
de´ce`s neurologique et d’e´valuer leur qualite´
me´thodologique, avec pour but d’informer et d’appuyer
les nouvelles lignes directrices canadiennes de prise en
charge des donneurs d’organes.
Me´thodologie A` la suite d’une recherche syste´matique,
nous avons inclus tout document endosse´ par un organisme
de dons d’organes, une socie´te´ professionnelle ou un
gouvernement et ayant pour but d’orienter la prise en
charge me´dicale des donneurs adultes d’organes multiples
a` la suite d’un de´ce`s neurologique. Nous avons extrait les
recommandations touchant six domaines : la tempeˆte
cate´cholaminergique, l’instabilite´ he´modynamique, la
supple´mentation hormonale, la ventilation, les
transfusions de produits sanguins et les soins ge´ne´raux a`
l’unite´ de soins intensifs (USI). La qualite´ me´thodologique
des lignes directrices a e´te´ e´value´e avec l’outil valide´
AGREE-II.
Constations principales Cette revue porte sur 27 guides
d’exercice cliniques repre´sentant 26 pays et publie´s entre
1993 et 2019. En se fondant sur l’outil valide´ AGREE-II
pour l’e´valuation de la qualite´ des lignes directrices, les
documents ont en re`gle ge´ne´rale obtenu un bon score en ce
qui touchait a` leurs objectifs et a` la clarte´ de leur
pre´sentation. Toutefois, la qualite´ e´tait limite´e en matie`re
de rigueur scientifique employe´e pour la mise au point des
lignes directrices. Les recommandations variaient
conside´rablement concernant les questions pertinentes a`
la prise en charge de la tempeˆte cate´cholaminergique, a` la
prise en charge subse´quente de l’instabilite´
he´modynamique, a` l’hormonothe´rapie, a` la ventilation
me´canique, a` la transfusion de produits sanguins, et aux
soins ge´ne´raux a` l’USI. A` la suite de la publication d’une
e´tude clinique importante, les recommandations
concernant la ventilation a` volume courant bas e´taient
constantes.
Conclusion Le manque de cohe´rence des lignes
directrices touchant les soins aux donneurs de´ce´de´s
re´sume´es dans cette revue est probablement le reflet de
l’e´mergence relativement lente de recherches cliniques de
qualite´ e´leve´e dans ce domaine, ainsi que de l’adoption
tardive des me´thodologies re´centes et valide´es pour
l’e´laboration de lignes directrices. Meˆme dans le
contexte actuel de rarete´ d’e´tudes randomise´es
controˆle´es, notre groupe appuie la ne´cessite´ de nouvelles
lignes directrices canadiennes concernant la prise en
charge des donneurs d’organes qui respectent une
me´thodologie reconnue et rigoureuse ainsi qu’une
classification des donne´es probantes.
Enregistrement de l’e´tude PROSPERO
(CRD42018084012); enregistre´e le 25 fe´vrier 2016.
Keywords organ donation  brain death  organ donor 
clinical practice guidelines  systematic review
Organ transplantation saves lives and improves quality of
life for thousands of chronically ill patients every year.1,2
In the United States in 2018, 113,000 patients were
K. Serri, MD  E. Charbonney, MD, PhD
Faculte´ de Me´decine, Universite´ de Montre´al, Montreal, QC,
Canada
Centre de recherche CIUSSSS du Nord de L’Ile, Hoˆpital du
Sacre´-Coeur de Montre´al, 5400 Gouin Ouest, Montre´al, QC H4J
1C5, Canada
Department of Medicine, Hoˆpital du Sacre´-Cœur de Montre´al,
Montreal, QC, Canada
F. D’Aragon, MD, MSc
Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC,
Canada
M. O. Meade, MD, MSc
Department of Medicine, McMaster University, Hamilton, ON,
Canada
123
1840 A. J. Frenette et al.

registered on a transplant waiting list, and 20 people died
every day while waiting for a transplant.2 In 2012, the
World Health Organization called for research to improve
the hospital care of deceased organ donors.3 While research
in this field is limited, current findings support the concept
that improved organ donor care can increase the quantity
and quality of organs for transplantation.4,5 Therefore,
evidence-based recommendations are an important tool to
guide best practices for the care of deceased donors in
intensive care units (ICUs).6 Nevertheless, rigorous highgrade evidence in the organ donor care field is lacking and
guidelines derived from expert consensus opinions may
represent the highest evidence to guide clinicians’
practices.
In the past years, research in organ donor care has been
slowly emerging, with the publication of randomized
trials.4,5 If guidelines are not preceded by a systematic
review of the evidence or lack mandatory update
mechanisms or processes to dictate recommendations,
they can rapidly become outdated, futile, and may lead to
inappropriate clinical decisions. Hence, the quality of
clinical decisions may suffer from misguided decisions,
and ultimately the donor and recipient outcomes may be
negatively affected by suboptimal clinical management.
Literature search citations
(n =24 733) 
Grey literature reports
(n=17)
Unique citations
(n = 22 450)
Selection for full text 
review
(n = 128) 
Excluded citations
(n=118) 
Reviews (n=43) 
Clinical study (n=9)
Letter or communication 
(n=16) 
Population (n=27)
Organization paper 
(n=14)
Local protocol (n=4)
Other (n=5)
Eligible guidelines
(n = 10)
Total guidelines eligible for review
(n = 27)
Fig. 1 Guideline selection flow
diagram
123
Worldwide Management of Donors 1841

For example, failure to include the recent
recommendation to administer mild hypothermia7,8 to
organ donors in specific guidelines, either because the
publication was not detected or because of a subjective
decision to ignore the recommendation, could jeopardize
kidney function in recipients around the world.4
This review was conducted concomitantly with and in
preparation for the 2020 Canadian guideline on organ
donor management.9 The objective was to inform and
support future Canadian guidelines by identifying and
systematically reviewing existing guidelines for organ
donor care, with the aim of listing and describing the
recommendations and evaluating their methodological
quality. We hypothesized that actual guidelines would
suffer from low methodological rigor and that our
systematic review could emphasize the need for
evidence-based Canadian guidelines.
Methods
The protocol of the present systematic review was
registered on PROSPERO and its last edition occurred on
1 June 2018 (CRD42018084012).
Literature search
In collaboration with a senior information specialist, we
searched ten bibliographic databases from their inception:
MEDLINE (Appendix 1), EMBASE, CisMef, Open Grey,
LILACS, SciELO, NICE, Cochrane Database of
Systematic Reviews, Global Health, and Base de
Donne´es de Sante´ Publique. We adapted the search
strategy to French and Spanish languages for specific
databases. To capture grey literature, we used Google (June
2020 for English, French, Spanish, Portuguese, Italian,
Chinese, and German and February 2016 for Japanese and
Arabic), we searched the TRIP database (28 May 2020)
and we requested unpublished guidelines from each
donation organization represented in the International
Fig. 2 Risk of bias assessment using the AGREE-II instrument
123
1842 A. J. Frenette et al.

Table 1 Description of the included guidelines
Country, (first author/subcategory)
Year (reference number)
Organizations Language Source
Ireland (Conrick-Martin)
201935
Intensive Care Society of Ireland English Peer review publication
India (Pandit)
201734
Indian Society of Critical Care Medicine English Peer review publication
Australia
201627
New South Wales Australia Ministry of Health English Website
Austria
201637
Gesundheit Oesterreich German Website
Germany
201638
Consul for Organ Donation; German Foundation for
Organ Transplantation
German Website
Norway
201644
Norks Ressursgruppe for Organdonasjon Norwegian Website
Denmark
201539
Neuro Anesthesia Committee of the Danish Society
of Anesthesia and Intensive Care Medicine;
Danish Neurological Society;
Danish Transplantation Society
Danish Website
Europe (Eurotransplant)
201529
Eurotransplant Foundation English Website
USA (Kotloff)
201532
Society of Critical Care Medicine; American
College of Chest Physicians; Association of
Organ Procurement Organizations; Donor
Management Task Force
English Peer review publication
Iran (Firoozifar)
201430
English Peer review publication
Switzerland (Haberthur)
201446
Fondation Suisse pour le Don d’Organes; Socie´te´
Suisse de Me´decine Intensive; Swisstransplant
French Website
Oceania (ANZICS)
201325
ANZICS English Website
Hungary
201340
Debrecen University;
Hungarian blood services
Hungarian Website
Brazil (Westphal)
201119–21
Brazilian Association of Intensive Care Medicine;
Brazilian Association of Organ Transplants;
Transplantation Centre of Santa Catarina
English and Portuguese Peer review publication
Canada (Bourret)
20108
Transplant Que´bec English Peer review publication
(abstract) and website
Chile (Rojas)
201041
Sociedad Chilena de Trasplante Spanish Peer review publication
Canada (Trilium)
201042
Trillium Gift of Life Network English and French Website
Cuba (Nodal Arruebarrena)
200943
Spanish Peer review publication
Australasia
200826
Australasian Transplant Coordinators Association English Website
Canada (Shemie)
200647
Canadian Critical Care Society; Canadian
Association of Transplantation;
Socie´te´ canadienne de transplantation; le Conseil
Canadien pour le Don et la Transplantation
English and French Peer review publication
France (Boulard)
20057
Socie´te´ Francaise d’Anesthe´sie et de Re´animation;
Socie´te´ de Re´animation de Langue Franc¸aise;
Agence de la biome´decine
French Peer review publication
123
Worldwide Management of Donors 1843

Table 1 continued
Country, (first
author/subcategory)Year
(reference number)
Organizations Language Source
United Kingdom
200533
Intensive care society UK;
British transplant society
English Website
USA (Powner)
200431
English Peer review publication
Slovenia (Avsec-Letonja)
200345
Slovenian Personal communication
USA(Baldwin)
199328
English Peer review publication
Argentina
?24
Institute Nacional Centre unico Coordinator de
Ablacion e Implante; Sociedad Argentina de
Terapia Intensiva; Sociedad Argentina de
Trasplante; Asociacion Argentina de Procuracion
de Organos y Tejidos para Transplante; Ministerio
de Salud
Spanish Website
Spain (Escudero)
?23
Red/consejo iberoamericano de donacion y
trasplante;
Servicio de Medicina Intensiva; Coordinacio´n de
Trasplantes Hospital Universitario Central de
Asturias
Spanish Website
Table 2 Hemodynamic targets
Country (first
author /
subcategory)
Year (reference
number)
Blood pressure targets Heart
rate
target
Hemodynamic parameters targets Echocardiography
indication and targets
Ireland (ConrickMartin)
201935
MAP 60–70 mmHg CVP 6–10 mmHg
PACWP 8–12 mmHg
CI [2.4 Lmin-1
m-2
All donors
Target:
LVEF C 45%
India (Pandit)
201734
SBP[100 mmHg
MAP C 60–70 mmHg
CVP 6–8 mmHg
PACWP 8–12 mmHg
Stroke volume variance \12%
CI 2.4 Lmin-1
m-2
All donors (fluid
response)
Unstable donors
Target
LVEF C 45%
Australia
201627
SBP[ 100 mmHg
MAP [60–80 mmHg
60–120
bpm
CVP 6–10 mmHg
CI [2.5 Lmin-1
m-2
Unclear
Austria
201637
MAP 65–75 mmHg 60–120
bpm
CVP 6–12 mmHg Unstable donors
Germany
201638
MAP 70–100 mmHg Vascular resistance 2000 ?/- 500
dynessec-1
cm-5
CVP 7–10 mmHg
PACWP\12 mmHg
CI 3–5 Lmin-1
m-2
ITBVI [850–1000 mLm-2
ELWI 3–7 mLkg-1
Stroke volume index 40–60 mLm-2
Unstable donors
Norway
201644
MAP [65 mmHg 60–120
bpm
CVP 6–10 mmHg
123
1844 A. J. Frenette et al.

Table 2 continued
Country (first
author /
subcategory)Year
(reference number)
Blood pressure targets Heart
rate
target
Hemodynamic parameters targets Echocardiography
indication and targets
Denmark
201539
MAP [60–70 mmHg CVP 6–10 mmHg All donors
Europe
(Eurotransplant)
201529
SBP C 90
MAP C 70–90 mmHg
CVP 6–10 mmHg
PACWP 10–15 mmHg
ITBVI 750–1000 mLm-2
Heart donor
USA (Kotloff)
201532
MAP C 60 mmHg CVP and/or PAC Heart donor
Target: [ 45%
Iran (Firoozifar)
201430
SBP C 100 mmHg
MAP C 60 mmHg, for patients[ 60
years old aim for MAP equal to age
70–100
bpm
CVP C 12 cmH2O, up to 15 cmH2O if donor[
60 yr old
Heart donor
Switzerland
(Haberthur)
201446
MAP 65–90 mmHg 60–120
bpm
CVP 8–12 mmHg
PACWP 10–15 mmHg
GEDVI 680–800 mLm-2
CI [2.5 Lmin-1m-2
EVLWI: \7 mLkg-1
PPV: \10%
All donors (baseline)
Unstable donors
Oceania
(ANZICS)
201325
MAP [70 mmHg
Hungary
201340
MAP 65–75 mmHg Vascular resistance: C 1200 dynessec-1cm-5
CVP 6–12 mmHg
PACWP 6–12 mmHg
Brazil (Westphal)
201119–21
SBP[ 90 mmHg
MAP [65 mmHg
CI [2.5 Lmin-1m-2 Unstable donors
Target:
LVEF [50%
Canada (Bourret)
20108
SBP 100–160 mmHg
MAP 65–90 mmHg
60–120
bpm
Vascular resistance 800–1200
dynessec-1
cm-5CVP 5–10 mmHg,
Heart donors
Target:
LVEF [50%
Chile (Rojas)
201041
MAP C 60 CVP 6–10 mmHg (if heart or lungs are not
considered, CVP[10 mmHg is acceptable)
Canada (Trilium)
201042
SBP 100–160 mmHg
MAP 70–90 mmHg
60–120
bpm
Vascular resistance 800–1200
dynessec-1
cm-5
CVP 6–10 mmHg
Heart donor
Target: LVEF[40%
Cuba (Nodal
Arruebarrena)
200943
SBP C 100 mmHg B 100
bpm
CVP 10–12 mmHg
PACWP 10–12 mmHg
Australasia
200826
MAP [70 mmHg
Canada (Shemie)
200647
SBP C 100 mmHg
MAP C 70 mmHg
60–120
bpm
Vascular resistance 800–1200
dynessec-1
cm-5
CVP 6–10 mmHg
PACWP 6–10 mmHg
CI [2.4 Lmin-1
m-2
All donors (baseline)
Heart donors
bpm = beatsmin-1
; CI= cardiac index; CVP = central venous pressure; DBP = diastolic blood pressure; EVLWI = extravascular lung water
index; GEDVI = global end-diastolic volume index; ITBVI = intrathoracic blood volume index; LVEF = left ventricular ejection fraction; MAP
= mean arterial pressure; PAC = pulmonary artery catheter; PACWP = pulmonary artery catheter wedge pressure; PPV = pulse pressure
variation; SBP = systolic blood pressure; TTE = transthoracic echocardiogram
123
Worldwide Management of Donors 1845

Table 3 Hemodynamic therapies
Country, (first
author /
subcategory)
Year (reference
number)
Fluid therapy Vasopressors Inotropic support
Therapy Contraindicated
solutions
Ireland (ConrickMartin)
201935
RL, NS, or balanced
crystalloids
2nd line: colloid solutions
Vasopressin 0.5–2.5 Uhr-1
2nd line: NE or phenylephrine
Dobutamine or
adrenaline
Limit dobutamine to
10 lgkg-1
min-1
India (Pandit)
201734
 NS or balanced
crystalloid solutions (RL
or Plasmalyte-A)
2nd line: albumin 20% or 4%
Avoid fluid
containing D5%
Avoid starches
Vasopressin 2.4 Uhr-1
2nd line: norepinephrine, epinephrine,
phenylephrine
3rd line: dopamine
Australia
201627
Balanced crystalloids
2nd line: albumin 4%, 20%
Starches
Gelatins
NE ad 0.2 lgkg-1
min-1
2nd line: add vasopressin 1.2–2.4 Uhr-1
Dobutamine
2nd line: epinephrine
Austria
20167
1st line: 1/2NS?D5% Starches NE, dopamine, phenylephrine, vasopressin Dobutamine,
isoproterenol,
levosimendan,
milrinone
2nd line : NE
Germany
201638
RL or NS
2nd line: albumin 5%
Starches NE
2nd line: vasopressin 1 U bolus then 0.5–4
Uhr-1
Dobutamine,
dopamine
Norway
201644
Ringer acetate, NS, D5%.
2nd line: 2:1 mix crystalloids
and colloids (albumin 5%
or dextran)
Starches Dopamine, NE, or vasopressin 1 U bolus then
0.5–2.5 Uhr-1
Dopamine 2–20
lgkg-1
min-1
Denmark
201539
Balanced crystalloids and
consider blood products
Starches
Albumin (caution)
Dopamine up to 10 mgkg-1min-1
2nd line: NE ad 0.1 lgkg-1min-1
3nd line: add vasopressin 0.4–5 Uhr-1
Dobutamine,
dopamine, or
epinephrine
Europe
(Eurotransplant)
201529
D5%, NS, D2.5%-0.45
saline, RL
2nd line: 2:1 mix
crystalloid/colloid
Dopamine ad 10 lgkg-1
min-1
2nd line: NE \ 0.2 lgkg-1min-1
USA (Kotloff)
201532
NS or RL Starches Dopamine up to 10 lgkg-1min-1
2nd line: vasopressin 0.01–0.04 Umin-1
Dopamine,
dobutamine, or
epinephrine
Iran (Firoozifar)
201430
RL or NS
2nd line: albumin or
gelofusin
Dopamine ad 10 lgkg-1
min-1
2nd line: NE
Dopamine
2nd line: epinephrine
(congestive heart
failure)
Switzerland
(Haberthur)
201446
NS or RL
2nd line: HES 130/0.4,
gelatin
HES 130/0.4 or
gelatin (caution if
renal failure)
NE 0.5–3 lgkg-1
min-1
2nd line: vasopressin 0.5–2.4 Uhr-1
Dobutamine B 5
lgkg-1
min-1
Oceania
(ANZICS)
201325
NE
Hungary
201340
Maintenance D5% HES 0.4/6%
(caution)
NE 0.01–2.5 lgkg-1min-1
2nd line: vasopressin 0.01–0.04 Umin-1 alone
or in combination with NE
Combination
dobutamine/NE ad
10 lgkg-1
min-1
2nd line: dopamine 4–
10 lgmin-1
Brazil (Westphal)
201119–21
Crystalloid solution NE, epinephrine or dopamine
2nd line: vasopressin 1 U bolus then 0.5–2.5
Uhr-1
Dobutamine
123
1846 A. J. Frenette et al.

Registry in Organ Donation and Transplantation (IRODaT)
database.10 Lastly, we examined the references of each
guideline included in this review. This literature search is
up to date as of May 2020.10
Eligibility criteria
This review includes any document endorsed by an organ
donation organization (ODO), a professional society, or a
government, that aims to direct the medical management of
adult, neurologically deceased, multi-organ donors,
including clinical goals, therapies, diagnostics, or
monitoring. This review excludes recommendations for
organ donation following a circulatory determination of
death, living organ donation, and paediatric organ
donation. We also excluded hospital protocols and
checklists, organ-specific recommendations for donor
care, and review articles. Organ donor care in the ICU
relies mostly on hemodynamic management and
interventions that may have multi-organ effects. For this
reason, we excluded organ-specific recommendations.
Nevertheless, this exclusion criterion was not applied at
the search strategy level to reduce the risk of publication
bias. The manual screening permitted us to confirm that
organ-specific recommendations pertained to the
management of recipients, which was outside the scope
of this review. Table 1 presents data for all guidelines, and
all other tables present data pertaining to guidelines
released after the 2006 Canadian guidelines were
published.
Guidelines selection
Two independent reviewers (A.J.F., and one of E.C.,
D.R.W., K.S., F.D.A., M.W., B.R., D.B., I.B.) screened
titles and abstracts generated from the literature search
using Covidence software (Veritas Health Innovation,
Melbourne, Australia),11 and reviewed full text reports for
all potentially relevant citations. A third independent
reviewer resolved disagreements. Where more than one
citation reported a guideline for one organization, the most
recent version was included.
Table 3 continued
Country, (first
author /
subcategory)Year
(reference
number)
Fluid therapy Vasopressors Inotropic support
Therapy Contraindicated
solutions
Canada (Bourret)
20108
D5%-1/2NS maintenance,
NS
2nd line: albumin
Starches (renal
failure)
Vasopressin B 2.4 Uhr-1
2nd line : NE \0.2 lgkg-1min-1
3rd line: epinephrine 0.2 lgkg-1min-1 or
phenylephrine 0.2 lgkg-1
min-1 or
dopamine B 10 lgkg-1
min-1
Chile (Rojas)
201041
RL or NS
2nd line: gelatin (lung
donors)
Dopamine ad 10 lgkg-1
min-1
2nd line: add NE
Epinephrine or
dobutamine
Canada (Trilium)
201042
Crystalloids Vasopressin ad to 2.4 Uhr-1
2nd line: dopamine 5–10 lgkg-1min-1
3rd line: NE ad 20 lgmin-1, epinephrine up to
20 lg

min-1, phenylephrine ad 200
lgmin-1
Cuba (Nodal
Arruebarrena)
200943
Mix 65% crystalloids-35%
colloids
2nd line: starches, gelatin
Dopamine ad 3 lgkg-1
min-1
2nd line: add noradrenaline 0.1 lgkg-1min-1
Dobutamine 5–15
lgkg-1
min-1
Australasia
200826
NE
2nd line: vasopressin 0.5–4 Uhr-1
Limit use
Canada (Shemie)
2006047
Vasopressin 2.4 Uhr-1
2nd line: NE, epinephrine and/or phenylephrine
max 0.2 lgkg-1
min-1
Dopamine B 10
lgkg-1
min-1
HES = hydroxyethyl starch; NE = norepinephrine; NS = normal saline; RL = Ringer lactate
123
Worldwide Management of Donors 1847

Table 4 Hormone therapies
Country (first
author /
subcategory)
Year (reference
number)
Combined hormone therapy Additional
corticosteroids
specific details
Additional thyroid
hormones details
Additional insulin
details
Additional antidiuretic
hormone analogues
details
Components Indications
Ireland (ConrickMartin)
201935
Vasopressin
Insulin
Thyroid
hormones
Corticosteroids
Hemodynamic
instability,
impaired
cardiac
function in
potential heart
donor
Specific
indication:
Shock
reversal: MP
1 g iv q24h
Specific indication:
Hemodynamic
instability: T3 4
lg iv then 3
lghr-1
Specific indication:
Glycemic control:
iv insulin for
glycemia
\10 mmolL-1
Specific indication:
Hemodynamic
instability:
vasopressin 1 U iv
bolus then 2.4 Uhr-1
Specific indication:
Diabetes insipidus:
DDAVP 1–2 lg iv or
SC PRN or
vasopressin 0.5–2.4
Uhr-1
India (Pandit)
201734
Vasopressin
Insulin
Thyroid
hormones
Corticosteroids
Refractory
hemodynamic
instability
MP 15 mgkg-1
iv q24hr or
250 mg iv
then 100
mghr-1
T4 20 lg bolus iv
then 10 lghr-1
infusion or T4
300–400 lg PO
q8h or T3 (if
available)
Specific indication:
Glycemic control:
Insulin for
glycemia 80–150
mgdL-1
Vasopressin 0.5–4
Uhr-1 iv infusion
Specific indication:
Diabetes insipidus:
DDAVP 10 lg
intranasal, 1–2 puffs
q4h or vasopressin
0.5–2 Uhr-1 iv
infusion
Australia
201627
Unclear Not formally
recommended,
consider if
LVEF\ 45%
or heart/lung
donors
MP 15 mgkg-1
iv x 1
T3 iv 4 lghr-1 Specific indication:
Glycemic control:
Insulin for glycemia
6–10 mmolL-1
Specific indication:
Diabetes insipidus:
DDAVP 1–4 lg iv q4-
8h PRN or
vasopressin 0.04–2.4
Uhr-1 iv infusion
Austria
201637
Specific
indication:
Persistent
hypotension:
hydrocortisone
200 mg iv
then 200
mg24 hr-1
Specific indication:
Glycemic control:
Insulin iv infusion 5
Uhr-1 and for
glycemia 80–150
mgdL-1
Specific indication:
Diabetes insipidus:
desmopressin iv 1–4 lg
q6-8h
Germany
201638
Unclear Hemodynamic
instability
MP 15 mgkg-1
Specific
indication:
All donors
Specific indication:
Diabetes insipidus:
DDAVP 1–4 lg iv PRN
Norway
201644
Unclear Hemodynamic
instability
MP 15 mgkg-1
Specific
indication:
All donors
Specific indication:
Diabetes insipidus:
DDAVP 1–4 lg iv
PRN
123
1848 A. J. Frenette et al.

Table 4 continued
Country (first
author /
subcategory)Year
(reference
number)
Combined hormone therapy Additional
corticosteroids
specific details
Additional thyroid
hormones details
Additional insulin
details
Additional antidiuretic
hormone analogues
details
Components Indications
Denmark
201539
Unclear Hemodynamic
instability
MP 15 mgkg-1
iv q24h
T3 4 lg iv then 3
lghr-1 infusion
or T4 20 lg iv
bolus, then 10
lghr-1 infusion
or T4 2 lgkg-1
tablets PO
Specific indication:
Unstable donor
with LVEF\45%
Not recommended
alone
Specific indication:
Glycemic control:
insulin for
glycemia 6–10
mmolL-1
Specific indication:
Diabetes insipidus:
desmopressin 1–2 lg
iv q6h PRN or nasal
spray 10–20 lg or
melting tablet 60–120
lg
Europe
(Eurotransplant)
201529
Specific indication:
Glycemic control
Specific indication:
Diabetes insipidus:
DDAVP 2–4 lg iv
USA (Kotloff)
201532
Thyroid
hormones
Corticosteroids
LV dysfunction
in potential
heart donors;
unmet
hemodynamic
goals and/or
LVEF \45%
(unclear)
MP 15
mgkg-1
, 1g
or 250 mg iv
then 100
mghr-1
infusion
T4 20 lg iv then 10
lghr-1 OR T3 4
lg iv then 3
lghr-1
Specific indication:
Glycemic control:
insulin for glycemia
\ 180 mgdL-1
Specific indication:
Diabetes insipidus:
DDAVP 1–4 lg iv or
vasopressin
Iran (Firoozifar)
201430
Unclear Hemodynamic
instability
MP 15 mgkg-1
iv q12h
T4 0.6 mg per
nasogastric tube
x1
Insulin 1 Uhr-1 and
scale adjustment
to glycemia\140
Specific indication:
Diabetes insipidus:
desmopressin 2–4 lg
nasal
Switzerland
(Haberthur)
201446
Unclear Hemodynamic
instability or
cardiac failure
Hydrocortisone
50 mg iv q6h
Specific
indication:
Lung donors:
MP 15 mgkg-1
T3 4 lg iv then 3
lghr-1 or T4 20
lg v then 10
lghr-1 or TSH
0.1 mg iv
Specific indication:
Refractory
hemodynamic
instability:
Glucose 10%-
Insulin-Potassium
infusion 1
mLkg-1
Specific indication:
Glycemic control:
iv insulin for
glycemia 4–8
mmolL-1
Specific indication:
Diabetes insipidus:
desmopressin 0.25–2 lg
iv q6h or vasopressin
0.5–2.0 Uhr-1
Oceania
(ANZICS)
201325
Vasopressin
Thyroid
Corticosteroids
Potential heart
donor with
LVEF\ 45%
MP 15 mgkg-1
iv x1
T3 4 lg iv bolus then
3 lghr-1
Specific indication:
Glycemic control
Vasopressin 0.5–4.0
Uhr-1
Specific indication:
Diabetes insipidus:
DDAVP 2–4 lg iv
q2-6 h
Worldwide Management of Donors 1849
123

Table 4 continued
Country (first
author /
subcategory)Year
(reference
number)
Combined hormone therapy Additional
corticosteroids
specific details
Additional thyroid
hormones details
Additional insulin
details
Additional antidiuretic
hormone analogues
details
Components Indications
Hungary
201340
Vasopressin
Insulin
Thyroid
Corticosteroids
Refractory
hemodynamic
instability
Hydrocortisone
50 mg iv
bolus then 50
mg x 4 doses
Specific
indication:
All lung
donors:
MP 15 mgkg-1
q24h
T3 4 lgkg-1 iv
bolus then 3
lghr-1
10 u bolus then
adjust to target
glycemia 4.2–8.3
mmolL-1
Specific indication:
Glycemic control:
insulin sliding
scale
Vasopressin 1 U bolus
then 0.6–2.4 Uhr-1
Specific indication:
Diabetes insipidus:
desmopressin 0.6–2 lg
iv q6-12h or nasal
spray 10–20 lg q12h
or vasopressin 0.01–
0.04 Umin-1 iv
Brazil (Westphal)
201119–21
Unclear All donors MP 15 mgkg-1 T3 4 lg v then 3
lghr-1 OR T4 20
lg iv then by 10
lghr-1 OR T4 1–
2 lgkg-1 PO
Specific indication:
Glycemia control:
iv insulin for
glycemia \180
mgdL-1
Specific indication:
Diabetes insipidus:
DDAVP 1–2 lg iv q4h
PRN to achieve and/
or vasopressin 1 U iv
then 0.5–2.4 Uhr-1
Canada (Bourret)
20108
Vasopressin
Thyroid
hormones
Corticosteroids
Refractory
hemodynamic
instability
MP 15 mgkg-1
iv max 1 g
q24h
Specific
indication:
Lung donors
T4 20 lg then 10
lghr-1 or 100 lg
then 50 lg iv q12h
Specific indication:
Glycemic control
Specific regimen: iv
insulin scale to
glycemia 4–8
mmolL-1
Specific indication:
Diabetes insipidus:
DDAVP 1–4 lg iv then
1–2 lg iv q6h PRN
Chile (Rojas)
201041
Vasopressin
Thyroid
hormones
Corticosteroids
Refractory
hemodynamic
instability
MP iv 15
mgkg-1 x1
Specific
indication:
Lung donors
T3 4 lg bolus than 3
lghr-1
Specific indication:
Glycemic control:
iv insulin for
glycemia 80–150
mgdL-1
Vasopressin 1 U bolus
then 0.5–4 Uhr-1
Specific indication:
Diabetes insipidus:
Vasopressin 1 U iv then
0.5–4 Uhr-1 or
DDAVP nasal/IM/SC
10–20 lg or DDAVP
iv 0.1–0.2 mL q8-12h
Canada (Trilium)
201042
Vasopressin
Thyroid
hormones
Corticosteroids
All donors
hemodynamic
instability
MP 15 mgkg-1
iv bolus (max
1 g) q24h
Specific
indication:
Lung donors
T4 100 lg iv then 50
lg iv q12 or 20 lg
iv then 10 lghr-1
Specific indication:
Glycemic control:
insulin for glycemia
6–10 mmolL-1
Vasopressin B 2.4
Uhr-1
Specific indication:
Diabetes insipidus:
DDAVP 4 lg iv q6h
PRN or vasopressin
0.5–2.4 Uhr-1
Cuba (Nodal
Arruebarrena)
200943
Unclear Refractory
hemodynamic
instability
Insulin iv 1 Uhr-1
adjust to target
120–180 mgdL-1
Specific indication:
Glycemic control
Specific indication:
Diabetes insipidus:
DDAVP 0.5–2 lg iv or
nasal drops 10–20 lg
or inhalation 10 lg
q8-12h, or
vasopressin
Australasia
200826
Vasopressin
Thyroid
hormones
Corticosteroids
Refractory
hemodynamic
instability and/
or LVEF \
45%
MP 15 mgkg-1
iv x1
T3 4 lg iv, then 3
lghr-1
Glycemic control
Specific regimen:
Insulin for glycemia
5–8 mmolL-1
Vasopressin 0.5–4
Uhr-1
Specific indication:
Diabetes insipidus:
DDAVP 2–4 lg iv q2-
6h or vasopressin
0.5–2 Uhr-1
1850 A. J. Frenette et al.
123

Quality assessments
Four reviewers independently assessed the methodological
rigour of every guideline using the validated AGREE-II
tool.12–14 AGREE-II evaluates the quality of guidelines
across six domains: 1) scope and purpose, 2) stakeholder
involvement, 3) rigour of development, 4) clarity of
presentation, 5) applicability, and 6) editorial
independence. Each domain contains specific items12–14
that reviewers can assess to rate the domain on a sevenpoint scale. In reporting the quality of guidelines, we
determined the scaled domain score reported as a
percentage of the maximum score, across four reviewers
for each AGREE-II domain.15 As suggested by the
AGREE-II manual, we created a three-point classification
of ‘‘low quality’’ (\ 40%), ‘‘moderate quality’’ (40–70%),
and ‘‘high quality’’ ([ 70%) and transposed the domain
scores.15 We also assessed inter-rater reliability among the
four reviewers using two-way random intraclass
correlations (ICC), and arbitrarily defined reliability as
low (ICC: 0–0.4), moderate (ICC: 0.41–0.79), and high
(ICC: 0.8–1.0).12 These analyses were performed with IBM
SPSS Statistics v24.0 2018 (IBM Corp., Armonk, NY,
USA).
Data extraction
A pre-tested form was used for data collection. This data
collection form was designed and reviewed in
collaboration with all the group investigators. The same
reviewers, in duplicate, extracted descriptive information
and specific donor management recommendations
pertaining to six key organ donor care interventions
domains: the autonomic storm, hemodynamic instability,
hormone supplementation, ventilation, blood product
transfusions, and general ICU care.16,17
Information synthesis
We used narrative data synthesis to report guidelines
recommendations with the aim of mapping the nature of
recommendations as well as describing their frequency
among international guidelines. Discrepancies between
investigators concerning the interpretation of
recommendations were discussed and resolved among the
group. Because risks that are inherent to most systematic
reviews were not measured, no meta-analysis was possible.
We have summarized the information in tables.
This report used a systematic methodology adapted from
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses statement (PRISMA).18 We apply the term
‘‘recommend’’ in this report without distinguishing strong
from weak recommendations, since only one of the original
guidelines19–21 clearly distinguished strong from weak
using a grading approach.22
Results
Description of guidelines
This review includes 27 clinical practice guidelines from
26 countries (Fig. 1). Guidelines were released between
1993 and 2019 (two had no release date)23,24 and most
were reported in English.19–21,25–35 Ten of 27 were
published in peer-reviewed journals
(Table 1).7,8,19–21,28,30–32,34–36
Quality of guidelines
The quality of guidelines data are presented in Fig. 2. In
assessing guideline quality, the inter-rater agreement
among four raters varied across domains. Raters achieved
Table 4 continued
Country (first
author /
subcategory)Year
(reference
number)
Combined hormone therapy Additional
corticosteroids
specific details
Additional thyroid
hormones details
Additional insulin
details
Additional antidiuretic
hormone analogues
details
Components Indications
Canada (Shemie)
200647
Vasopressin
Thyroid
hormones
Corticosteroids
All donors
LVEF B 40% or
hemodynamic
instability
MP 15 mgkg-1
max 1 g
Specific
indication:
Lung donors
T4 lg iv then 10
lghr-1 or T4 100
lg iv then 50 lg iv
q12h
Specific indication:
Glycemic control:
insulin for
glycemia 4–8
mmolL-1
Vasopressin B 2.4
Uhr-1
Specific indication:
Diabetes insipidus:
DDAVP 1–4 lg iv then
1–2 lg iv q6h OR
vasopressin B 2.4 U
DDAVP = 1-desamino-8-d-arginine vasopressin; LVEF = Left ventricle ejection fraction; MP = methylprednisolone; IM = intramuscular; SC =
subcutaneous; TSH = thyroid stimulating hormone; T3 = triiodothyronine; T4 = thyroxine
Worldwide Management of Donors 1851
123

high agreement for domains 1, 2, and 3 in the majority of
guidelines. Most guidelines scored moderately well on the
clarity of their scope (e.g., specific purpose, target
clinicians) (domain 1),7,19–21,23,24,26,29,30,37–43 and the
clarity of their recommendations (domain
4).8,19–21,27,29–31,33,35,37–40,42,44,45 Most guidelines scored
low on other domains. Stakeholder involvement (domain 2)
was limited: many did not appear to involve members of
the public, and/or representatives from all target clinician
groups.7,8,26,27,29,30,34,35,38–40,42,43,46 Almost all guidelines
lacked an explicit and research-based approach for
formulating their recommendations (domain
3).7,8,23–31,33–35,37–48 For example, only two guidelines
mentioned a systematic search of the literature.19–21,39 Two
guidelines, however, determined the strength of
recommendations using a grading approach,19–22,34 and
one reported the agreement between experts on specific
recommendations.7 In terms of applicability (domain 5), all
guidelines but one47 lacked information on facilitators or
barriers to their application and no monitoring or auditing
criteria were described (domain 5). Finally, only three of
27 reported an approach to conflict of interest in guideline
development or presentation (domain 6).32,34,47 Although
guidelines in this review were released over a 25-year
period, we subjectively did not observe a clear
improvement in methodological quality in the most
recent, except for the purpose and scope (domain 1).
Recommendations
Management of the autonomic storm
The autonomic storm is usually defined as an adrenergic
period surrounding brain stem herniation that presents with
hypertension, tachycardia, and cardiac dysfunction.49,50
Fourteen guidelines (14/27; 51.9%) described the
importance of the autonomic storm,19–21,23–28,32–35,39,43,44
but less than half provided recommendations about
diagnosis24,28,32–34,43,44 or treatment
strategies.23,25,27,28,32–34,44,46 Seventeen guidelines (17/27;
63.0%) recommended specific medications for
hypertension and tachycardia8,23–29,31,34,37,39,41–43,45–47;
most commonly esmolol24–27,34,37,39,41,43,46 and
nitroprusside because of their short-acting,
titratable effects.24–27,34,39,46 Alternatives included various
classes of anti-hypertensive agents and remifentanil.
Because of the transient nature of the autonomic storm
and the risk of subsequent hypotension, four guidelines
recommended not treating hypertension or tachycardia in
this setting, or limiting treatment to very severe
cases.19–21,26,27,34
Hemodynamic management after the autonomic storm
Recommended targets for mean arterial pressure ranged
from 60 mmHg to 100 mmHg
(Table 2).7,8,19–21,23–27,29–42,44,46,47 As first-line
vasopressors, most documents recommended
norepinephrine7,19–21,23,25–27,38,40,46 and/or
dopamine19–21,23,24,28–30,32,39,41,43,45 (Table 3).
Vasopressin was the preferred agent in Canadian,8,36,42,47
Irish,35 Indian,34 and UK guidelines,33 potentially because
of its additional value in the management of diabetes
insipidus. Epinephrine was variably suggested as an
alternative agent,19–21 or as a last choice of
vasopressors,8,24,34,36,42,45,47 or it was contraindicated
altogether.40 No clear temporal effect was observed over
the years on the choice of vasopressors. Nevertheless, we
detected a consistent but nonpersistent recommendation on
dopamine as a first-line therapy between 2014 and 2016,
potentially in reaction to a trial published in 2009.51
In terms of fluid management, crystalloids were
generally recommended as a first-line
solution,8,19–21,24,26–33,35,37,38,40–42,46 and some documents
recommended colloids along with
crystalloids.7,23,24,29,39,43,45,46 Four guidelines (4/27;
14.8%) recommended intravenous starches,7,40,43,46 and
nine (9/27; 33.3%) strongly recommended against starch
therapy, particularly for donors with renal
failure.8,24,26,27,32,34,37–39,44,46 The guidelines
recommending starches were all released in 2005–2013,
before or in the years surrounding general ICU and organ
donor literature studies that changed practice against their
use52–54; two of the guidelines identified a maximal dose
not to be exceeded, which was related to the risk of acute
kidney injury.7,40 Three guidelines (3/27; 11.1%)
recommended a daily negative or neutral fluid balance to
facilitate lung donation.24,27,35
In terms of inotropic agents,
dobutamine,7,17–19,23,24,27,31,35,37–39,41,45,46
epinephrine,7,24,27,32,35,39 and dopamine24,31,36,38,39,47 were
all recommended most commonly; other agents included
isoproterenol,37 levosimendan,37 milrinone,37 and
norepinephrine.24,37 The inconsistent indications for each
related to various clinical measures of impaired cardiac
function.7,19–21,23,24,27,30–32,34–37,39–41,43,44,46,47 Six
guidelines (6/27; 22.2%) made no recommendation on
inotropic therapies.8,25,28,29,33,42
Fourteen guidelines (14/27; 51.9%) recommended
‘‘usual care’’ for arrhythmias,19–21,23,25–27,32,34,38,40,41,43–46
and amiodarone was the most commonly recommended
drug.19–21,23,25–27,34,44,46 For bradyarrhythmias, seven
reports (7/27; 25.9%) recommended cardiac
pacing19–21,23,27,40,44,46 or beta-agonist
agents,19–21,23,27,34,38,40,44,46 citing the lack of effect of
1852 A. J. Frenette et al.
123

atropine19–21,25,27,34,40,44–46 or glycopyrrolate27 after brain
death. Seven guidelines (7/27; 25.9%) addressed cardiac
arrest among deceased donors, and recommended routine
cardiopulmonary resuscitation.19–21,23,25,39,41,45,46
In terms of monitoring, most guidelines recommended
central venous pressure (CVP) monitoring, with target
ranges from 4 to 15 mmHg.8,23,24,27,29–31,33–
3840–44,46,47 Guidelines frequently recommended
echocardiography to guide hemodynamic
therapy,7,8,19–21,23,24,27–39,42,46,47 with minimum targets of
left ventricular ejection fraction ranging from 40% to
50%.8,19–21,24,34,35,38,39,42,46 In addition, 19 documents (19/
27; 70.3%) stated various indications for pulmonary artery
catheterization, including young donors,41 potential heart
or lung donors,24,30 donors with heart dysfunction or
pulmonary hypertension,17–19,21,31,35,42,46,47 or for all
refractory unstable donors.8,23,24,34,37,38,42,44,45,47
Hormone therapy
Every guideline addressed hormone supplementation
(Table 4). Nineteen (19/27; 70.4%) recommended
corticosteroid therapy.7,8,19–21,24–27,30,32,34,35,39–44,46,47,49
Four (4/27; 14.8%) recommended steroids for all
donors32,38,39,44; three (3/27; 11.1%) recommended
steroids for hemodynamically unstable donors,23,35,37 and
others recommended steroids only if there was the potential
for donation of the lungs,8,23,24,27,40–42,46,47 heart,27 or
liver.46 The most common dosing strategy was high-dose
methylprednisolone.8,19–21,23–27,30,32,34,35,37–42,44,46,47 The
recommendation of high-dose corticosteroids was
consistent over time and did not seem to be affected by
the publication of two systematic reviews questioning their
use.48,55
Eighteen guidelines (18/27; 66.7%) recommended
thyroid hormone
supplementation.7,8,19–21,24–27,30,32,34,35,39–43,46,47
Indications included all donors34 or those with
hemodynamic instability.27,31,35,39,46 Suggested agents
included triiodothyronine (T3; six guidelines),25–27,39–41
thyroxine (T4; four guidelines),8,30,42,47 or either (six
guidelines).19–21,24,32,34,38,46 Three guidelines (3/27;
11.1%) did not recommend routine thyroid
supplementation based on the lack of supporting
evidence.23,28,45 Two of them26,45 were published before
a systematic review showing the lack of evidence for the
use of thyroid hormone supplementation56; the publication
date of the third guideline is unknown.24
Nine guidelines (9/27; 33.3%) addressed insulin therapy
for organ donors.24,27,30,34,35,39,40,43 Some recommended
insulin for all donors,30,40,43 potentially for its possible
inotropic effect, while others recommended insulin as
needed for glycemic control, similarly to ICU general care
practice.8,19–21,23,25–27,29,31–35,37–42,46,47 For the latter,
dosing ranges and glycemic targets varied. One guideline
recommended a mixed infusion of glucose, insulin, and
potassium (GIK) for donors with refractory hemodynamic
instability.46
Vasopressin was suggested as a component of a
hormone therapy bundle in 13 guidelines (13/27;
48.1%),7,8,24–26,34,35,39–43,47 in doses ranging from 0.4 to
5 Uhr-1
.
19–21,23–27,33,34,40–42,47 Desmopressin, a synthetic
analogue of vasopressin that lacks the vasopressor
properties, was recommended as first-line therapy for
diabetes insipidus in 23 guidelines (23/27; 85.2%), with or
without combined vasopressin
infusion.7,8,19–21,23–27,30–32,34,35,37–40,42–47
Lung protective mechanical ventilation
All but three (24/27; 88.8%)25,26,28 reports provided
recommendations on ventilation parameters and/or
arterial blood gas targets (Table 5). Recommended tidal
volume ranges were from 4–12
mLkg-1
.
8,19–21,24,27,29–31,35,38–42,46,47 Eleven guidelines
(11/27; 40.7%) recommended low tidal volumes (4–8
mLkg-1
) for all donors,8,19–21,27,29,35,38,40–42,44,46 and four
(4/27; 14.8%) specifically for lung donors.19–21,23,24,39
Almost all guidelines that recommended lung protective
strategy in donors19–21,27,29,30,35,39,40,44,46 were released
after the publication of a lung protective strategy trial in
lung donors.5 Earlier, a trial on lung protective strategy in
general ICU ARDS patients57 might also have influenced
the recommendations of previous guidelines.8,29,41,42,47
Recommendations on maximal peak airway pressures
ranged from 30 cmH2O to 47
cmH2O,8,29–31,36,38,40–43,46,47 maximal plateau airway
pressures ranged from 30 to 35
cmH2O,19–21,23,24,27,31,35,38,46 and eight guidelines (8/27;
29.6%) made recommendations about recruitment
maneuvers.7,8,19–21,23,24,27,31,32,35,38,42,47 Only the
Brazilian guideline recommended advanced ventilation
strategies in cases of respiratory failure.19–21
Blood product transfusions
All but one guideline25 made recommendations about
blood product transfusion. Hemoglobin transfusion
thresholds varied from 70 to 100
gL-1,7,8,19–21,23,24,26,27,29,30,32–34,37,42–47 and some
guidelines provided hematocrit thresholds, which ranged
from 20% to 30%.24,28–31,34,38,40,41,44–46 Only a few
guidelines distinguished stable from unstable donors in
making these recommendations.19–21,23,27
Recommendations for platelet and coagulation factor
transfusions appeared in nine guidelines (9/27;
Worldwide Management of Donors 1853
123

33.3%).7,19–21,24,27,31,38,40,41,43,46 Threshold platelet levels
varied from 20 to 150 x 109
gL-1.
7,19–21,24,27,31,40,41,46
Recommendations for plasma or fibrinogen transfusions
were inconsistent; some required active
bleeding,8,19–21,29,35,42,43,47 while others required only
coagulopathy.8,19–21,23–25,27,31,33,34,38,41,43 Fibrinolytic
therapy (with tranexamic acid, aprotinin, or aminocaproic
acid) was recommended in one guideline46 and not
recommended in another because of potential thrombosis
risk.33
General ICU care
Twenty-three reports (23/27; 85.2%) addressed body
temperature, with recommended ranges falling between
35 and 38C.7,8,19–21,23,26,27,29–31,34,35,37–43,46
Recommendations for the management of hyperthermia
included antibiotics,27,31,39,42 antipyretics
(acetaminophen),27,31,39 and external cooling.27,28,31,39,42
Recommendations for preventing or treating hypothermia
included various warming
strategies.8,19–21,23,25,26,29–31,33–35,37,38,40–46 No guideline,
including those released after the 2015 study suggesting
protective results of mild hypothermia on recipients renal
outcomes,4 clearly recommended its use.
Most guidelines recommended continuation of
previously initiated enteral8,19–21,25,32,34,35,39,42,46,47 or
parenteral nutrition,8,32,35,42,46,47 and five guidelines (5/
27; 18.5%) suggested initiating enteral
nutrition.8,19–21,35,42,47 One guideline recommended
discontinuation of all nutritional support in potential
donors, but did not explain why.44
Three reports (3/27; 11.1%) addressed stress ulcer
prophylaxis,31,39,40 one recommending daily intravenous
pantoprazole.31 Mechanical and/or pharmacological
thromboprophylaxis was recommended by two guidelines
(2/27; 7.4%).27,35 Eight guidelines (8/27; 29.6%) suggested
antimicrobial prophylaxis, including eight different agents
or classes.7,22,24,28,29,32,39,44 Six other guidelines (6/27;
22.2%) strongly recommended against routine
antimicrobial prophylaxis.27,34,43,46,47
Discussion
This systematic review uniquely summarizes 27 guidelines
for the management of neurologically deceased organ
donors. The results summarize the most recent versions of
clinical practice guidelines endorsed by organ donation
organizations, medical societies, and governments around
the world, whether published in peer-reviewed sources or
not. A vast majority originated from Europe, North
America, and Australia. Striking observations from this
review include the inconsistency of recommendations
across guidelines, the low uptake of evidence-based
literature, the lack of systematic updating processes, and
most importantly, the absence of rigorous methodology.
With a paucity of clinical research in this field, and
particularly randomized trials,4,5,51 medical guidelines tend
to emphasize physiologic reasoning and expert
opinion,58,59 an approach that lends itself to subjectivity
and selective reporting.58,60
With the assessment of potential benefits and risks,
guidelines are first meant to help clinicians choose the best
options for their patients.61 Secondly, guidelines help to
nuance certainty around clinical decisions by incorporating
an evaluation of the quality of the evidence.22,62 Our
systematic review clearly showed that because of their poor
methodology, the available guidelines for the care of organ
donors around the world fail to achieve both these goals.
First, to choose the best option for a donor, bedside
clinicians need to evaluate the whole body of literature in a
glimpse, and to summarize the effect of interventions, a
heavy task that guidelines can facilitate. Nevertheless, the
vast majority of available guidelines on organ donor care
do not base their recommendations on systematic reviews
of the literature, so do not draw a clear picture of available
options and their impact. As a consequence of an arbitrary
selection of the evidence, recommendations vary largely
around the world, and sometimes fail to integrate the most
recent trials. As an example, actual best evidence supports
the use of moderate hypothermia in donors to improve
kidney recipient outcomes.4 Nevertheless, none of the
guidelines released after this randomized-controlled study
was published incorporated this information in their
recommendations. Whether the study was not identified,
its results were deliberately ignored, or its results were
judged as irrelevant or biased is unknown. The counterexample is the immediate adoption of the lung protective
ventilation strategy emanating from an underpowered
randomized-controlled trial by the majority of guidelines.5
Conversely, interventions such as corticosteroid
supplementation are widely recommended in the
guidelines, although not supported by published
literature.55 In this situation, actual guidelines fail to
indicate to clinicians the level of certainty surrounding the
recommendation, and do not acknowledge potential
theoretical but unstudied risks related to corticosteroids
(e.g., hyperglycemia or infection in donors). We believe
that not grading the evidence and not evaluating the
internal and external validity of studies supporting the
recommendations could lead to overconfidence in futile
interventions, to variability in practices, and to misses in
research opportunities.63
The quality of guidelines in the organ donation field can
be improved through a systematic validated methodology
1854 A. J. Frenette et al.
123

along with a grading of the evidence. In a recent joint effort
of the Society of Critical Care Medicine, the American
College of Chest Physicians, and the American Association
of Organ Procurement Organizations to produce evidencebased guidelines for deceased donor care, authors reasoned
that because ‘‘…the available literature was
overwhelmingly composed of observational studies and
case series, … a decision was made that the document
would assume the form of a consensus statement rather
than a formally graded guideline.’’32 Following the present
systematic review, where we observed inconsistent
recommendations and persistent lack of rigorous
methodology over more than 20 years, our group
supported the need for an evidence-based Canadian
guideline for the management of organ donors. To fulfill
its mandate, the group for the Canadian guidelines for the
management of organ donors conducted systematic reviews
of the literature on every pre-identified PICO (patient,
intervention, comparator, outcome) question.9 When
possible, estimates were pooled and calculated, and
recommendations were based on the known benefit or
harm. The group who developed the Canadian guidelines
for the management of organ donors accompanied every
recommendation with its level of certainty, as
recommended by GRADE methodology.9,22
In clinical fields such as cardiology and oncology,
adherence to guidelines has shown a potential to improve
clinical decision processes and clinical outcomes.64–66
Guideline adherence in organ donation was not extensively
studied, but was reported as low to moderate.67 Given our
observations, we believe that asking if inconsistent
recommendations and poor methodological quality of
guidelines have an influenced adherence is a legitimate
question. Now that the Canadian guidelines for the
management of organ donors are published, research groups
should evaluate their acceptance and compliance by clinicians.
Then, studies can evaluate the direct impact of guidelines on
donors and recipients’ outcomes. Well conducted guidelines
should also encourage and trigger randomized studies in
nested areas, studies that would then systematically be
incorporated in future guidelines through a standardized
audit and update mechanism. Although we should be careful
not to fall into self-fulfilling prophecy, we believe that,
informed by this systematic review, the Canadian guidelines
for the care of organ donors have succeeded in their mission.
We have to acknowledge a few limitations to our work.
First, we did not evaluate if each guideline’s
recommendation was scientifically sound or clinically
appropriate; an assessment of the content validity of
current guideline individual recommendations was
beyond the scope of this review. It is also possible that
individual hospitals have developed their own documents
to supplant the relatively older guidelines included in this
review. In addition, although we thoroughly searched for
the international guidelines, some areas of the globe where
organ donor care could take place are underrepresented
(Asia, Africa). Finally, although the AGREE-II is the most
frequently recommended validated tool to evaluate the
quality of reporting for guidelines, we could not overcome
its intrinsic limitations.12–14
The strengths of this review include the broad search for
relevant guidelines, the systematic assessment of guideline
quality using a validated instrument, and duplicate
independent data abstraction. To date, this is the only
systematic review of guidelines for organ donation, and the
findings highlight important opportunities to advance
deceased donor care through improved guideline
methodology that will incorporate emerging high-quality
research.
Conclusion
This systematic review highlighted that existing guidelines
for the management of organ donors suffer from
inconsistent recommendations and poor methodological
quality. It achieved its goal in informing and supporting the
Canadian guidelines for the management of organ donors.
In this new age of randomized trials in deceased donor
care, we can look forward to more frequent guideline
updates, stronger recommendations, and stronger
justification for the standardization of care. An agenda
establishing priorities for research could lead to the
development of high-quality guidelines to improve
transplant outcomes, as shown in other fields of
healthcare.68–70
Author contributions Anne Julie Frenette, David Williamson,
Maureen O. Meade, and Emmanuel Charbonney contributed to all
aspects of this manuscript, including study conception and design;
acquisition, analysis, and interpretation of data; and drafting the
article. Matthew-John Weiss, Bram Rochwerg, Ian Ball, Dave
Brindamour, Karim Serri, and Frederick D’Aragon contributed to
the conception and design of the study, the acquisition of data, and
interpretation of data.
Disclosures None.
Funding statement None.
Editorial responsibility This submission was handled by Dr. Alana
M. Flexman, Associate Editor, Canadian Journal of Anesthesia.
References
1. Burra P, De Bona M. Quality of life following organ
transplantation. Transpl Int 2007; 20: 397-409.
Worldwide Management of Donors 1855
123

2. Health Resources & Services Administration. Organ donation
statistics, 2019. Available from URL: https://www.organdonor.
gov/statistics-stories/statistics.html (accessed July 2020).
3. Canadian Blood Services; World Health Organization.
International Guidelines for the Determination of Death - Phase
1. Montreal Forum Report 2012. Available from URL: https://
www.who.int/patientsafety/montreal-forum-report.pdf (accessed
July 2020).
4. Niemann CU, Feiner J, Swain S, et al. Therapeutic hypothermia
in deceased organ donors and kidney-graft function. N Engl J
Med 2015; 373: 405-14.
5. Mascia L, Pasero D, Slutsky AS, et al. Effect of a lung protective
strategy for organ donors on eligibility and availability of lungs
for transplantation: a randomized controlled trial. JAMA 2010;
304: 2620-7.
6. Hoste P, Vanhaecht K, Ferdinande P, et al. Care pathways for
organ donation after brain death: guidance from available
literature? J Adv Nurs 2016; 72: 2369-80.
7. Boulard G, Guiot P, Pottecher T, Tenaillon A. Management of
subjects in a state of brain death and the preservation of organs.
Ann Fr Anesth Reanim 2005; 24: 836-43.
8. Bourret M, Marsolais P, Langevin S. Adults guidelines organ
donor assessment and management. Transplantation 2010; DOI:
https://doi.org/10.1097/00007890-201007272-01037.
9. Ball IM, Hornby L, Rochwerg B, et al. Management of the
neurologically deceased organ donor: A Canadian clinical
practice guideline. CMAJ 2020; 192: E361-9.
10. International Registry in Organ Donation and Transplantation
(IRODaT). Available from URL: http://www.irodat.org/ (accessed July 2020).
11. Elliott J. Covidence(R). [Software] 2010. Available from URL:
https://www.covidence.org/home (accessed July 2020).
12. Brouwers MC, Kho ME, Browman GP, et al. Development of the
AGREE II, part 1: performance, usefulness and areas for
improvement. CMAJ 2010; 182: 1045-52.
13. Brouwers MC, Kho ME, Browman GP, et al. Development of the
AGREE II, part 2: assessment of validity of items and tools to
support application. CMAJ 2010; 182: E472-8.
14. AGREE Collaboration. Development and validation of an
international appraisal instrument for assessing the quality of
clinical practice guidelines: the AGREE project. Qual Saf Health
Care 2003; 12: 18-23.
15. AGREE Collaboration. The Appraisal of Guidelines for Research
& Evaluation (AGREE) Instrument. Available from URL: www.
agreetrust.org (accessed July 2020).
16. Meyfroidt G, Gunst J, Martin-Loeches I, et al. Management of the
brain-dead donor in the ICU: general and specific therapy to
improve transplantable organ quality. Intensive Care Med 2019;
45: 343-53.
17. Korte C, Garber JL, Descourouez JL, Richards KR, Hardinger K.
Pharmacists’ guide to the management of organ donors after brain
death. Am J Health Syst Pharm 2016; 73: 1829-39.
18. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group.
Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Med 2009; DOI: https://
doi.org/10.1371/journal.pmed.1000097.
19. Westphal GA, Caldeira Filho M, Vieira KD, et al. Guidelines for
potential multiple organ donors (adult): part II. Mechanical
ventilation, endocrine metabolic management, hematological and
infectious aspects. Rev Bras Ter Intensiva 2011; 23: 269-82.
20. Westphal GA, Caldeira Filho M, Vieira KD, et al. Guidelines for
potential multiple organ donors (adult). Part III: organ-specific
recommendations. Rev Bras Ter Intensiva 2011; 23: 410-25.
21. Westphal GA, Caldeira Filho M, Vieira KD, et al. Guidelines for
potential multiple organ donors (adult): part I. Overview and
hemodynamic support. Rev Bras Ter Intensiva 2011; 23: 255-68.
22. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus
A. GRADE guidelines: a new series of articles in the Journal of
Clinical Epidemiology. J Clin Epidemiol 2011; 64: 380-2.
23. Escudero D. Mantenimiento del donante multiorganico.
Available from URL: http://files.sld.cu/trasplante/files/2010/07/
mantenimiento.pdf (accessed July 2020).
24. Anonymous. Procurar para curar; manual de tratamiento del
donante a corazon batiente. Available from URL: https://www.
incucai.gov.ar/files/docs-incucai/Materiales/profesionales/06-
manual_procurar_para_curar.pdf (accessed July 2020).
25. Australian and New Zealand Intensive Care Society. The
ANZICS statement of death and organ donation (Edition 3.2),
2013. Available from URL: https://www.anzics.com.au/wpcontent/uploads/2018/08/ANZICS_Statement_on_Death_and_
Organ_Donation_Edition_3.2.pdf (accessed July 2020).
26. Australasian Transplant Coordinators Association Inc. National
guidelines for organ and tissue donation (4th Edition), 2008.
Available from URL: http://www.atca.org.au/files/F.pdf
27. Office of the Chief Health Officer. Management of the Adult
Brain Dead Potential Organ and Tissue Donor - 2016. Available
from: https://www1.health.nsw.gov.au/pds/
ActivePDSDocuments/GL2016_008.pdf (accessed July 2020).
28. Baldwin JC, Anderson JL, Boucek MM, et al. 24th Bethesda
Conference: Cardiac Transplantation. Task force 2: Donor
guidelines. J Am Coll Cardiol 1993; 22: 15-20.
29. Eurotransplant Foundation. Eurotransplant Manual, version 5.5,
2016. Available from URL: https://www.eurotransplant.org/wpcontent/uploads/2020/01/H1-Introduction.pdf (accessed July
2020).
30. Firoozifar M, Khosravi MB, Ghafari S, et al. Shiraz guideline for
the management of patients with brain death. Int J Organ
Transplant Med 2014; 5: 34-7.
31. Powner DJ, Darby JM, Kellum JA. Proposed treatment guidelines
for donor care. Prog Transplant 2004; 14: 16-26.
32. Kotloff RM, Blosser S, Fulda GJ, et al. Management of the
potential organ donor in the ICU: Society of Critical Care
Medicine/American College of Chest Physicians/Association of
Organ Procurement Organizations consensus statement. Crit Care
Med 2015; 43: 1291-325.
33. Intensive Care Society UK Transplant. Guidelines for Adult
Organ and Tissue Donation. Available from URL: http://www.
clodlog.com/resources/Documents/UK-ICS-Guidance-2005.pdf
(accessed July 2020).
34. Pandit RA, Zirpe KG, Gurav SK, et al. Management of potential
organ donor: Indian Society of Critical Care Medicine: position
statement. Indian J Crit Care Med 2017; 21: 303-16.
35. Conrick-Martin I, Gaffney A, Dwyer R, et al. Intensive Care
Society of Ireland - Guidelines for management of the potential
organ donor (2018-2nd edition). Ir J Med Sci 2019; 188: 1111-8.
36. Shemie SD, Baker AJ, Knoll G, et al. National recommendations
for donation after cardiocirculatory death in Canada: donation
after cardiocirculatory death in Canada. CMAJ 2006; DOI:
https://doi.org/10.1503/cmaj.060895.
37. Gesundheit Osterreich. Intensivtherapie potenzieller
Organspender, 2016. Available from URL: https://transplant.
goeg.at/sites/transplant.goeg.at/files/2017-06/4_Intensivtherapie_
16_2.pdf (accessed July 2020).
38. Deutsche Stiftung Organtransplantation. Leitfaden fur die
Organspende. Available from URL: https://dso.de/organspende/
fachinformationen/organspendeprozess/leitfaden-f%C3%BCrdie-organspende (accessed July 2020).
39. Dansk Center for Organ Donation. Rekommandation;
Benhandling af organdonorer - 2015. Available from URL:
http://www.dasaim.dk/wp-content/uploads/2015/12/Rekomorgandonation-2015-okt_vs2_alle-dok-samlet.pdf (accessed July
2020).
1856 A. J. Frenette et al.
123

40. Zoltan S, Ilona O. Szervdonacio - Szakmai Kollegiumi Ajanlas,
2013. Available from URL: http://docplayer.hu/2182569-
Szervdonacio-szakmai-kollegiumi-ajanlas.html (accessed July
2020).
41. Rojas JL, Buchuk D. Seleccion y mantenimiento del donante de
organos para trasplante. In: Maturana MU (Ed.). Guias Clinicas
Sociedad Chilena de Trasplante. Grafhika Copy Center Ltd;
2010: 19-26. https://www.sociedaddetrasplante.cl/biblioteca/guias-cli-nicas-sociedad-chilena-de-trasplante.html (accessed July
2020).
42. Trillium Gift of Life Network. Tissue Donation Resource Manual,
2011. Available from URL: https://www.giftoflife.on.ca/
resources/pdf/Tissue_Donation_Resource_Manual_EN_(final).
pdf (accessed July 2020).
43. Nodal Arruebarrena JR, Marrero Rodriguez JN, Quintero
Menendez Y, Reyes Perez AM, Jova Duenas J. Guia de practica
clinica para el tratamiento del donante potencial de organos.
Revista Electronica de la Ciencias Medicas en Cienfuegos 2009;
7(Supp 1): 249-56.
44. Norsk ressursgruppe for Organdonasjon. Protokoll for
organdonasjon. Available from URL: http://www.norod.no/
protokoll-for-organdonasjon/ (accessed July 2020).
45. Avsec-Letonja D, Zabavnik Z. Vzdrzevanje Moznega Mrtvega
Darovalca Organiv in Tkiv V Intenzivni Terapiji.
Transplantacijska dejavnost 2003 [cited 2017]87-103];
Personnal communication.
46. Haberthur C, Revelly, JP, Stocker R. Recommendations pour le
traitement et le monitoring des donneurs d’organes adultes a`
coeur battant aux soins intensifs, version 3.0, 2014. Available
from URL: https://www.swisstransplant.org/fileadmin/user_
upload/Infos_und_Material/Swiss_Donation_Pathway/SDP_
modul_2_Bhdlg_des_erw_Spenders_FR_2014.pdf (accessed July
2020).
47. Shemie SD, Ross, H, Pagliarello, et al. La prise en charge des
donneurs d’organes au Canada: recommendations du forum
optimiser le maintien du donneur afin d’accroitre le nombre
d’organes admissibles pour la transplantation. CMAJ 2006; 174:
SF14-SF32.
48. D’Aragon F, Belley-Cote E, Agarwal A, et al. Effect of
corticosteroid administration on neurologically deceased organ
donors and transplant recipients: a systematic review and metaanalysis. BMJ Open 2017; DOI: https://doi.org/10.1136/
bmjopen-2016-014436.
49. Novitzky D, Wicomb WN, Cooper DK, Rose AG, Reichart B.
Prevention of myocardial injury during brain death by total
cardiac sympathectomy in the Chacma baboon. Ann Thorac Surg
1986; 41: 520-4.
50. Novitzky D, Wicomb WN, Cooper DK, Rose AG, Fraser RC,
Barnard CN. Electrocardiographic, haemodynamic & endocrine
changes occuring during experimental brain death in the Chacma
baboon. J Heart Transplant 1984; 4: 63-9.
51. Schnuelle P, Gottmann U, Hoeger S, et al. Effects of donor
pretreatment with dopamine on graft function after kidney
transplantation: a randomized controlled trial. JAMA 2009;
302: 1067-75.
52. Zarychanski R, Abou-Setta AM, Turgeon AF, et al. Association of
hydroxyethyl starch administration with mortality and acute
kidney injury in critically ill patients requiring volume
resuscitation: a systematic review and meta-analysis. JAMA
2013; 309: 678-88.
53. Demir A, Aydinli B, Toprak HI, et al. Impact of 6% starch 130/0.4
and 4% gelatin infusion on kidney function in living-donor liver
transplantation. Transplant Proc 2015; 47: 1883-9.
54. Myburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl starch or
saline for fluid resuscitation in intensive care. N Engl J Med
2012; 367: 1901-11.
55. Dupuis S, Amiel JA, Desgroseilliers M, et al. Corticosteroids in
the management of brain-dead potential organ donors: a
systematic review. Br J Anaesth 2014; 113: 346-59.
56. Macdonald PS, Aneman A, Bhonagiri D, et al. A systematic
review and meta-analysis of clinical trials of thyroid hormone
administration to brain dead potential organ donors. Crit Care
Med 2012; 40: 1635-44.
57. Acute Respiratory Distress Syndrome Network, Brower RG,
Matthay MA, Morris A, et al. Ventilation with lower tidal
volumes as compared with traditional tidal volumes for acute
lung injury and the acute respiratory distress syndrome. N Engl J
Med 2000; 342: 1301-8.
58. Ponce OJ, Alvarez-Villalobos N, Shah R, et al. What does expert
opinion in guidelines mean? a meta-epidemiological study. Evid
Based Med 2017; 22: 164-9.
59. Cooper DK, Novitzky D, Wicomb WN. The pathophysiological
effects of brain death on potential donor organs, with particular
reference to the heart. Ann R Coll Surg Engl 1989; 71: 261-6.
60. Kennedy PJ, Leathley CM, Hughes CF. Clinical practice
variation. Med J Aust 2010; 193(S8): S97-9.
61. Field MJ, Lohr KN. Clinical Practice Guidelines: Directions for a
New Program. Committee to Advise the Public Health Service on
Clinical Practice Guidelines, Institute of Medicine. Available
from URL: https://www.nap.edu/initiative/committee-to-advisethe-public-health-service-on-clinical-practice-guidelines. (accessed July 2020).
62. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical
guidelines: potential benefits, limitations, and harms of clinical
guidelines. BMJ 1999; 318: 527-30.
63. D’Aragon F, Lamontagne F, Cook D, et al. Variability in
deceased donor care in Canada: a report of the Canada-DONATE
cohort study. Can J Anesth 2020; 67: 992-1004.
64. Wo¨ckel A, Kurzeder C, Geyer V, et al. Effects of guideline
adherence in primary breast cancer–a 5-year multi-center cohort
study of 3976 patients. Breast 2010; 19: 120-7.
65. Komajda M, Lapuerta P, Hermans N, et al. Adherence to
guidelines is a predictor of outcome in chronic heart failure: the
MAHLER survey. Eur Heart J 2005; 26: 1653-9.
66. Wilke M, Grube RF, Bodmann KF. Guideline-adherent initial
intravenous antibiotic therapy for hospital-acquired/ventilatorassociated pneumonia is clinically superior, saves lives and is
cheaper than non guideline adherent therapy. Eur J Med Res
2011; 16: 315-23.
67. Hoste P, Ferdinande P, Vogelaers D, et al. Adherence to
guidelines for the management of donors after brain death. J Crit
Care 2019; 49: 56-63.
68. Hubbard IJ, Harris D, Kilkenny MF, et al. Adherence to clinical
guidelines improves patient outcomes in Australian audit of
stroke rehabilitation practice. Arch Phys Med Rehabil 2012; 93:
965-71.
69. Trogrlic Z, van der Jagt M, Lingsma H, et al. Improved guideline
adherence and reduced brain dysfunction after a multicenter
multifaceted implementation of ICU delirium guidelines in 3,930
patients. Crit Care Med 2019; 47: 419-27.
70. Tullius SG, Rabb H. Improving the supply and quality of
deceased-donor organs for transplantation. N Engl J Med 2018;
378: 1920-9.
Publisher’s Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Worldwide Management of Donors 1857
123

